WRF
ADPT icon

Waddell & Reed Financial’s Adaptive Biotechnologies ADPT Stock Holding History

Waddell & Reed Financial’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-24,696
Closed -$1.19M – 450
2019
Q2 		$1.19M Buy
+24,696
New +$1.09M ﹤0.01% 458

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TM
Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Waddell & Reed Financial's ADPT Position: Q3 2019 in Review

Waddell & Reed Financial sold out of Adaptive Biotechnologies (ADPT) in Q3 2019, closing a stake of 24,696 shares — an estimated $1.19M sold.

Waddell & Reed Financial first reported a position in ADPT in Q2 2019 and held it in 1 quarter. The position peaked at $1.19M in Q2 2019. 117 funds tracked by Wall St. Rank hold ADPT as of Q3 2019.

  • Waddell & Reed Financial reported no remaining Adaptive Biotechnologies position as of Q3 2019 after selling out during the quarter.
  • Waddell & Reed Financial sold 24,696 Adaptive Biotechnologies shares in Q3 2019, an estimated $1.19M.
  • Waddell & Reed Financial first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 1 quarter.
  • Waddell & Reed Financial's Adaptive Biotechnologies position peaked at $1.19M in Q2 2019.
  • 117 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2019.

Based on Waddell & Reed Financial's 13F filing for Q3 2019, filed 14 Nov 2019.